IL219504A - Quinazoline Compounds, Pharmaceuticals Containing Them and Using It to Prepare Medicines to Treat Heart Failure with Congestion - Google Patents

Quinazoline Compounds, Pharmaceuticals Containing Them and Using It to Prepare Medicines to Treat Heart Failure with Congestion

Info

Publication number
IL219504A
IL219504A IL219504A IL21950412A IL219504A IL 219504 A IL219504 A IL 219504A IL 219504 A IL219504 A IL 219504A IL 21950412 A IL21950412 A IL 21950412A IL 219504 A IL219504 A IL 219504A
Authority
IL
Israel
Prior art keywords
medicaments
preparation
pharmaceutical compositions
same
heart failure
Prior art date
Application number
IL219504A
Other languages
English (en)
Hebrew (he)
Other versions
IL219504A0 (en
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of IL219504A0 publication Critical patent/IL219504A0/en
Publication of IL219504A publication Critical patent/IL219504A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL219504A 2009-11-03 2012-04-30 Quinazoline Compounds, Pharmaceuticals Containing Them and Using It to Prepare Medicines to Treat Heart Failure with Congestion IL219504A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25764609P 2009-11-03 2009-11-03
PCT/US2010/054927 WO2011056740A1 (en) 2009-11-03 2010-11-01 Quinazoline compounds

Publications (2)

Publication Number Publication Date
IL219504A0 IL219504A0 (en) 2012-06-28
IL219504A true IL219504A (en) 2016-09-29

Family

ID=43970282

Family Applications (1)

Application Number Title Priority Date Filing Date
IL219504A IL219504A (en) 2009-11-03 2012-04-30 Quinazoline Compounds, Pharmaceuticals Containing Them and Using It to Prepare Medicines to Treat Heart Failure with Congestion

Country Status (13)

Country Link
US (1) US8859571B2 (https=)
EP (1) EP2501233B1 (https=)
JP (1) JP5836963B2 (https=)
KR (1) KR101736521B1 (https=)
CN (1) CN102711474B (https=)
AU (1) AU2010315361B2 (https=)
BR (1) BR112012010524A2 (https=)
CA (1) CA2779989A1 (https=)
EA (1) EA021439B1 (https=)
ES (1) ES2523465T3 (https=)
IL (1) IL219504A (https=)
MX (1) MX2012005155A (https=)
WO (1) WO2011056740A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5603883B2 (ja) * 2009-02-17 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング B−Rafキナーゼを阻害するためのピリミドピリミジン誘導体
CN103159685A (zh) * 2013-04-11 2013-06-19 苏州立新制药有限公司 4-氯-6,7-二(2-甲氧基乙氧基)喹唑啉的制备方法
JP6527513B2 (ja) * 2013-11-20 2019-06-05 シグナルケム・ライフサイエンシーズ・コーポレイションSignalchem Lifesciences Corporation Tamファミリーキナーゼ阻害剤としてのキナゾリン誘導体
CN105849044B (zh) 2013-12-26 2018-10-26 埃克森美孚研究工程公司 Zsm-48晶体的合成
CN111868039A (zh) * 2017-09-26 2020-10-30 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
JP7785663B2 (ja) 2019-09-16 2025-12-15 ノバルティス アーゲー 二機能性分解誘導薬及びそれらの使用方法
WO2023049312A1 (en) 2021-09-23 2023-03-30 Erasca, Inc. Egfr inhibitor polymorph forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
PT2213661E (pt) 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
CN103626742B (zh) * 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂

Also Published As

Publication number Publication date
ES2523465T3 (es) 2014-11-26
US8859571B2 (en) 2014-10-14
JP2013510155A (ja) 2013-03-21
JP5836963B2 (ja) 2015-12-24
CA2779989A1 (en) 2011-05-12
US20120220588A1 (en) 2012-08-30
EP2501233A1 (en) 2012-09-26
EA201290243A1 (ru) 2012-12-28
KR101736521B1 (ko) 2017-05-16
CN102711474A (zh) 2012-10-03
BR112012010524A2 (pt) 2017-12-12
KR20120112441A (ko) 2012-10-11
EP2501233B1 (en) 2014-09-24
WO2011056740A1 (en) 2011-05-12
MX2012005155A (es) 2012-08-31
CN102711474B (zh) 2014-09-10
AU2010315361A1 (en) 2012-05-24
AU2010315361B2 (en) 2014-06-12
EA021439B1 (ru) 2015-06-30
IL219504A0 (en) 2012-06-28
EP2501233A4 (en) 2013-06-19

Similar Documents

Publication Publication Date Title
IL268756B (en) Piperazine-2,5-dione derivatives, pharmaceutical preparations containing them and their use for the preparation of medicines
IL219309A (en) History of glycoside, including pharmaceutical preparations and their use in the preparation of diabetes medications
IL206952A (en) History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines
IL234166B (en) Isoindoline compounds, a pharmaceutical composition containing it and its use in the preparation of a medicine
IL215065A (en) Proline derivatives, their preparation process, their pharmaceutical compositions and their uses in drug preparation
IL212573A (en) Aryl Methyl Benzokinazulinone Compounds
IL213019A (en) Derivatives 1-Azo-3-Terroyl-Azoline, Pharmaceutical Preparations Containing and Using Them
IL253000A0 (en) Tricyclic pyrazolyl compounds, their use for the preparation of drugs for the treatment of cancer and pharmaceutical preparations containing them
IL233677A (en) Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition
PL2731947T3 (pl) Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
IL221160A (en) 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
IL217490A (en) History of pyridine-4-il, pharmaceutical preparations containing them and their use in the preparation of medicines
IL221146A (en) History of Pyridine 2,5- Two-Converted, Pharmaceutical Preparations Containing Them, and Their Use in the Preparation of Drugs for the Prevention and Treatment of Cancer
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
IL218169A (en) Quinazoline compounds and their pharmaceutical compositions containing them for use in therapy
IL222268A (en) Preserved pyrollo-pyridines, containing pharmaceutical preparations, combined preparations containing them and their use in the preparation of medicines
IL215799A (en) Quinazolone compounds, pharmaceuticals containing them and their uses
IL214098A (en) Derivatives of 2– (pyrolidine – 2 – il) - h1– benzimidazole, pharmaceutical preparations containing them and their use in the preparation of drugs
IL214309A (en) Preserved pyridines, pharmaceuticals containing them and their use in the preparation of medicines
IL199362A (en) Pyridopyrimidine Compounds, Pharmaceuticals, Compounds for Use as a Drug, and Compounds for Manufacture @ Drug
IL216006A (en) Processed aromatic compounds, pharmaceutical preparations including them and their use in the manufacture of pharmaceuticals
IL203936A (en) HISTORY 4 - Pyrimidinsulfamide, Process for Preparation, Pharmaceutical Preparations Containing and Using it for Medication Preparation
IL211842A (en) Antibodies or fragments of their human tgfbrii, pharmacological preparations containing them and their use in the preparation of a drug for inhibiting anogenesis

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees